ClinicalTrials.gov
ClinicalTrials.gov Menu

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02195349
Recruitment Status : Completed
First Posted : July 21, 2014
Last Update Posted : June 12, 2018
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV. GSK2831781 is a humanized Antibody Dependent Cell Cytotoxicity (ADCC) enhanced monoclonal afucosylated antibody that is specific to the Lymphocyte Activation Gene-3 (LAG-3) protein. This is the first administration of GSK2831781 in humans and will evaluate in two parts the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of single IV doses of GSK2831781 administered to healthy subjects previously vaccinated with Bacillus Calmette Guérin (BCG) (Part A delayed type hypersensitivity [DTH] cohorts) and patients with plaque psoriasis (Part B). The inclusion of DTH and psoriasis subjects to explore the mechanism in biopsies and clinical response endpoints in these populations, as well as investigate systemic biomarkers will provide useful information prior to conducting studies in other immune-inflammatory disease which will involve more invasive tissue biopsies. Measuring the pharmacology of GSK2831781 using the depletion of LAG-3+ T-cells in skin biopsies from Tuberculin Purified Protein Derivative (PPD) skin challenge and lesional skin biopsies from patients with psoriasis, will be helpful in understanding of the dose response relationship, which will be important for designing future studies in immuno-inflammatory diseases, including psoriasis. Approximately 67 subjects will be enrolled to complete dosing and critical assessments. The subject numbers will be split to approximately 40 healthy subjects (Part A) and 27 patients with psoriasis (Part B).

Condition or disease Intervention/treatment Phase
Psoriasis Biological: GSK2831781 Biological: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
Actual Study Start Date : July 30, 2014
Actual Primary Completion Date : March 7, 2018
Actual Study Completion Date : March 7, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Healthy Subjects (no DTH)
One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
Biological: GSK2831781
GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.

Biological: Placebo
Commercial saline solution administered by IV over approximately 2 hours

Experimental: Healthy Subjects (DTH)
Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
Biological: GSK2831781
GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.

Biological: Placebo
Commercial saline solution administered by IV over approximately 2 hours

Experimental: Subjects with Psoriasis
Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
Biological: GSK2831781
GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.

Biological: Placebo
Commercial saline solution administered by IV over approximately 2 hours




Primary Outcome Measures :
  1. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (No DTH) by measuring Vital signs [ Time Frame: Up to Day 189 ]
    Vital signs will include measurement of systolic and diastolic blood pressure, pulse rate and temperature, taken in semi-supine position after 5 minutes of rest

  2. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (DTH) by measuring Vital signs [ Time Frame: Up to Day 219 ]
    Vital signs will include measurement of systolic and diastolic blood pressure, pulse rate and temperature, taken in semi-supine position after 5 minutes of rest

  3. Assessment of Safety and tolerability of single IV doses of GSK2831781 in psoriasis patients by measuring Vital signs [ Time Frame: Up to Day 300 ]
    Vital signs will include measurement of systolic and diastolic blood pressure, pulse rate and temperature, taken in semi-supine position after 5 minutes of rest

  4. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (No DTH) by measuring 12-Lead Electrocardiogram (ECG) [ Time Frame: Up to Day 189 ]
    Heart rate, PR, QRS, QT, and Electrocardiogram QT interval corrected for heart rate using Fridericia's formula (QTcF intervals) will be recorded by measuring triplicate 12-lead ECGs, obtained in semi-supine position after 5 minutes rest ECG will be measured continuously during the IV infusion (0-2 hours) with only abnormalities entered into the database

  5. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (DTH) by measuring 12-Lead ECGs [ Time Frame: Up to Day 219 ]
    Heart rate, PR, QRS, QT, and QTcF intervals will be recorded by measuring triplicate 12-lead ECGs, obtained in semi-supine position after 5 minutes rest ECG will be measured continuously during the IV infusion (0-2 hours) with only abnormalities entered into the database

  6. Assessment of safety and tolerability of single IV doses of GSK2831781 in psoriasis patients by measuring 12-Lead ECGs [ Time Frame: Up to Day 300 ]
    Heart rate, PR, QRS, QT, and QTcF intervals will be recorded by measuring triplicate 12-lead ECGs, obtained in semi-supine position after 5 minutes rest ECG will be measured continuously during the IV infusion (0-2 hours) with only abnormalities entered into the database

  7. Safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (No DTH) as assessed by number of subjects with adverse events (AE) [ Time Frame: Up to Day 365 ]
    AEs will be collected from the start of Study Treatment and until the follow-up contact

  8. Safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (DTH) as assessed by number of subjects with AEs [ Time Frame: Up to Day 365 ]
    AEs will be collected from the start of Study Treatment and until the follow-up contact

  9. Safety and tolerability of single IV doses of GSK2831781 in volunteers with psoriasis, as assessed by number of subjects with AEs [ Time Frame: Up to Day 365 ]
    AEs will be collected from the start of Study Treatment and until the follow-up contact

  10. Assessment of Safety and tolerability of single IV doses of GSK2831781 in healthy subjects (No DTH) by measuring inflammatory cytokine levels [ Time Frame: Pre-dose, and at 6, 12, 24 and 48 hours post dose ]
    Cytokines for assessment may include but are not limited to Interleukin (IL)-6, Tumour necrosis factor alpha (TNFa), IL-8 and Interferon-gamma (IFN-gamma)

  11. Assessment of Safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (DTH) by measuring inflammatory cytokine levels [ Time Frame: Pre-dose, and at 6, 12, 24 and 48 hours post dose ]
    Cytokines for assessment may include but are not limited to IL-6, TNFa, IL-8 and IFN-gamma

  12. Assessment of Safety and tolerability of single IV doses of GSK2831781 in psoriasis patients by measuring inflammatory cytokine levels [ Time Frame: At pre-dose, and at 6, 12, 24 and 48 hours post dose ]
    Cytokines for assessment may include but are not limited to IL-6, TNFa, IL-8 and IFN-gamma

  13. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (no DTH) by measuring Laboratory safety data [ Time Frame: Up to Day 189 ]
    Laboratory safety data was assessed in terms of Haematology, Clinical Chemistry and Urinalysis

  14. Assessment of safety and tolerability of single IV doses of GSK2831781 in healthy volunteers (DTH) by measuring Laboratory safety data [ Time Frame: Up to Day 219 ]
    Laboratory safety data was assessed in terms of Haematology, Clinical Chemistry and Urinalysis

  15. Assessment of safety and tolerability assessment of single IV doses of GSK2831781 in psoriasis patients by measuring Laboratory safety data [ Time Frame: Up to Day 300 ]
    Laboratory safety data was assessed in terms of Haematology, Clinical Chemistry and Urinalysis


Secondary Outcome Measures :
  1. Change from baseline [Tuberculin Purified Protein Derivative (PPD) 1st challenge] of induration diameter from re-challenge at 3 days post-dose, in healthy volunteers (DTH) [ Time Frame: Baseline (Day1) and Day32 ]
    The induration of wheals is defined as an elevation and induration that develop as a result of intradermal immunization with PPD, and is measured in the vertical and horizontal plane using the ball point pen technique

  2. Duration of induration in the re-challenge (healthy volunteers DTH model) [ Time Frame: Day 30 ]
    The induration of wheals is defined as an elevation and induration that develop as a result of intradermal immunization with PPD. The duration of appearance of induration for the rechallenge dose of PPD is recorded

  3. Change from baseline (PPD 1st challenge) of Lymphocyte Activation Gene (LAG)-3+ cells in biopsies of re-challenged skin at 3 days post dose in healthy volunteers (DTH) [ Time Frame: Baseline(Day 1) and Day 32 ]
    A punch biopsy will be taken from the re-challenge site and will be processed for analysis by IHC or other techniques to characterise and count the LAG-3+ cells

  4. Change from baseline in LAG-3+ cells in lesional biopsies of psoriasis patients at Day 29 measured by IHC. [ Time Frame: Baseline and Day 29 ]
    A punch biopsy will be taken from one of the sites and processed for analysis by IHC or other techniques to characterise and count the LAG-3+ cells

  5. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (no DTH) for 0.0003mg/kg Cohort [ Time Frame: Pre dose, at 0.5, 1, 2, 4, 6, 8, 12 and 24, hours post dose and Follow up (Day 29) ]
    Analysis will be done using the PK parameters of maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma time curve [AUC(0-t), AUC(0-week4) and AUC(0-infinity)], percent AUC extrapolated, Last time point where the concentration is above the limit of quantification (tlast), Systemic clearance (CL), Volume of distribution at steady state (Vss), Mean residence time (MRT), terminal phase elimination rate constant (Lambda z), the number of points used to determine Lambda z and the terminal phase half-life (t1/2)

  6. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (no DTH) for 0.0015mg/kg Cohort [ Time Frame: Pre dose, at 0.5, 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours post dose and Follow up (Day 43) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  7. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (no DTH) for 0.0075mg/kg Cohort [ Time Frame: Pre dose, at 0.5, 1, 2, 4, 6, 8, 12, 24, 48,72, 168 hours, Day 15 post dose and Follow up (Day 85) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  8. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (no DTH) for 0.04mg/kg Cohort [ Time Frame: Pre dose, At 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 168 hours, Days 15, 22, 29, 43, 57 post dose and Follow up (Day 147) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  9. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (no DTH) for 0.15mg/kg Coh [ Time Frame: Pre dose, At 0.5, 1, 2, 4, 6, 8, 12, 24, 48,72, 168 hours, Days 15, 22, 43, 85 post dose and Follow up (Day 189) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  10. Composite of GSK2831781 PK parameters following single IV dose in healthy volunteers (DTH) for 0.15mg/kg Cohort [ Time Frame: Pre dose, At 0.5, 1, 2, 4, 6, 8, 12, 24, 48,72, 168 hours, Days 15, 22, 43, 85 post dose and Follow up (Day 219) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  11. Composite of GSK2831781 PK parameters following single IV dose for patients with psoriasis in 0.5mg/kg cohort [ Time Frame: Pre dose, at 0.5, 1, 2, 4, 6, 8, 12, 24, 48,72,168 hours, Days 15, 22, 29, 43, 85, 121 post dose and Follow up (Day 230) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  12. Composite of GSK2831781 PK parameters following single IV dose in patients with psoriasis for 1.5mg/kg cohort [ Time Frame: Pre dose, At 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72,168 hours, Days 15, 22, 29, 36, 43, 57, 85, 121 post dose and Follow up (Day 270) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  13. Composite of GSK2831781 PK parameters following single IV dose in subjects with psoriasis for 5mg/kg cohort [ Time Frame: Pre dose, At 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72,168 hours, Days 15, 22, 29, 43, 57, 71, 85, 121 post dose and Follow up (Day 300) ]
    Analysis will be done using the PK parameters of AUC(0-infinity), AUC(0-t), AUC(0-Week4), percent AUCex, Cmax, tmax, tlast, CL, Vss, MRT, Lambda z, number of points used to determine Lambda z and the t1/2

  14. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy volunteers (no DTH) For 0.0003MG/KG Cohort [ Time Frame: Up to Day 29 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  15. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy subjects (no DTH) For 0.0015MG/KG Cohort [ Time Frame: Up to Day 43 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  16. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy volunteers (no DTH) For 0.0075MG/KG Cohort [ Time Frame: Up to Day 85 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  17. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy volunteers (no DTH) For 0.004MG/KG Cohort [ Time Frame: Up to Day 147 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  18. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy volunteers (no DTH) For 0.15MG/KG Cohort [ Time Frame: Up to Day 189 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  19. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of healthy volunteers (DTH) For 0.15MG/KG Cohort [ Time Frame: Up to Day 219 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated immunoelectrochemiluminescent (ECL) assays. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  20. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of volunteers with psoriasis in 0.5 MG/KG cohort [ Time Frame: Up to Day 230 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated ECL assay. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  21. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of patients with psoriasis in 1.5 MG/KG cohort [ Time Frame: Up to Day 270 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated ECL assay. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  22. Immunogenicity of single IV dose of GSK2831781, measured in terms of antibodies to GSK2831781 in serum of patients with psoriasis in 5 MG/KG cohort [ Time Frame: Up to Day 300 ]
    Samples will be analyzed for the presence of anti-GSK2831781 antibodies using a validated ECL assay. Confirmed positive samples will be titrated to obtain the titre of the anti-GSK2831781 antibodies

  23. To evaluate the effect of a single IV dose of GSK2831781 on disease activity in patients with psoriasis by measuring the change from baseline and actual Psoriasis Area Severity Index (PASI) scores at Day 15, 29, 43, 85 and 121 [ Time Frame: Baseline, Up to Day 300 ]
    PASI score is a 0-6 point rating scale which is used to measure the psoriatic involvement for each area of the body (head, upper extremities, trunk, lower extremities)

  24. To evaluate the effect of a single IV dose of GSK2831781on disease activity in psoriasis patients by measuring the proportion of subjects achieving >=50 % and >=75 % improvement from baseline in PASI score at Day 15, 29, 43, 85 and 121 (PASI 50 and 75) [ Time Frame: Baseline, Up to Day 300 ]
    PASI score is a 0-6 point rating scale which is used to measure the psoriatic involvement for each area of the body (head, upper extremities, trunk, lower extremities)

  25. To evaluate the effect of a single IV dose of GSK2831781on disease activity in patients with psoriasis by measuring the change from baseline and actual Psoriatic Lesion Severity Scores (PLSS) at Day 15, 29, 43, 85 and 121 [ Time Frame: Baseline, Up to Day 300 ]
    PLSS is a 0 to 4 point rating scale for lesions and is the sum of the erythema, scaling and induration, measured by a qualified dermatologist

  26. Change from baseline and actual Physical Global Assessment (PGA) scores in patients with psoriasis at Day 15, 29, 43, 85 and 121 [ Time Frame: Baseline, Up to Day 121 ]
    A 7-point scoring system will be used to measure the severity of psoriatic lesions over the whole body, at the time of the evaluation will be performed

  27. Proportion of patients in each PGA score category among patients with psoriasis, at Day 15, 29, 43, 85 and 121 [ Time Frame: Baseline, Up to Day 121 ]
    Number of volunteers in each PGA score category will be measured



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Part A males aged between 18 and 65 years of age and Part B males and females aged between 18 and 75 years of age inclusive, at the time of signing the informed consent
  • Part A: A body weight <=120 kilogram (kg) and Body mass index (BMI) within the range 19-32 kg/square meter (m^2) (inclusive), Part B: BMI within range 19-35 kg/m^2 (inclusive).
  • Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent)
  • Based on single or averaged Electrocardiogram QT interval corrected for heart rate (QTc) values of triplicate Electrocardiogram (ECGs) obtained over a brief recording period: Electrocardiogram QT interval corrected for heart rate using Fridericia's formula (QTcF) <450 milliseconds (msec)
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

For Part A study subjects only

  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and 12-lead ECGs. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the Glaxosmithkline (GSK) Medical Monitor, if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures

Delayed type hypersensitivity (DTH) cohorts only

  • Subjects with a history of Bacillus Calmette Guérin (BCG) vaccination as evidence by either: A BCG scar and verbal confirmation of BCG vaccination ; Or documented medical history of a BCG vaccination with or without a BCG scar
  • Subjects with a history of current vaccination for Tetanus, diphtheria, measles, pertussis, mumps and rubella

For Part B study subjects only

  • Subject has psoriasis covering Body Surface Area (BSA) >=3 percent as assessed at Screening and Day-1
  • Subject has had a confirmed diagnosis of chronic plaque-type psoriasis (without recent documented flare within 30 days prior to screening) for at least 6 months
  • Subject has at least 2 stable plaques assessed at Screening and Day -1. One of a suitable size and in a site suitable for repeat biopsy, and one for index lesion Plaque Lesional Severity Score (PLSS) scoring. Both must have a PLSS lesional score of >=2 for the induration component (moderate or above), >=1 for erythema and scaling with a total score of >=5. The biopsy lesion must not be on the face, groin or scalp and must be protected from the sun
  • A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at screening and negative urine hCG test at Day -1 for Females of Reproductive Potential [FRP]), not lactating, and at least one of the given conditions applies: Non-reproductive potential defined as pre-menopausal females with a documented tubal ligation; or documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; or hysterectomy; or documented bilateral oophorectomy.

Postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

Reproductive potential and agrees to use a barrier method (male condom or female diaphragm) plus to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP from 28 days prior to the first dose of study medication and until completion of the follow-up visit.

The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. The investigator or designee should remind the subjects of the need to comply with these requirements approximately monthly, either at study visits or by telephone call until the follow-up visit.

Exclusion Criteria:

  • Received live vaccine (s) attenuated or recombinant within 4 weeks of Day 1 or plan to receive a live vaccination during the study until follow-up
  • Subjects from a high risk area of the world for tuberculosis or have history of tuberculosis or have close family members with confirmed Mycobacterium tuberculosis (MTB) infection or positive at screening by Quantiferon testing
  • Subject is unable to abstain from travelling to areas with high endemic rates of infectious diseases until the end of the follow up period
  • A medical history of severe allergic reaction, angio-edema, anaphylaxis or immunodeficiency
  • Subjects with neutrophil results below the normal range at screening and baseline
  • Subjects with any clinical, even mild, Gastrointestinal (GI) upset such as, but not limited to, diarrhea or abdominal cramping during the previous week before dosing, as well as history of more chronic GI upset, e.g. Irritable Bowel Syndrome (IBS)
  • Current evidence of ongoing or acute infection within 3 months prior to the first dose of study drug, such as: Serious local infection (e.g. cellulitis, abscess); Systemic infection [e.g. pneumonia, septicaemia, Tuberculosis (TB)]
  • Subjects who test positive for pre-existing ADA to GSK2831781 at screening.
  • History of malignancy, except for basal cell or squamous cell carcinoma, or in situ cervical carcinoma that has been fully treated and shows no evidence of recurrence
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8gram (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
  • History of sensitivity to any of the study medications or Tuberculin Purified Protein Derivative (PPD) challenge agent, or components thereof or a history of drug (or Immunoglobulin G therapeutic antibodies) or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • A positive pre-study drug/alcohol screen
  • A positive test for Human Immunodeficiency Virus (HIV) antibody
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Subjects with an aspartate aminotransferase and/or gamma glutamyltransferase level above the upper limit of normal at screening and/or baseline will be excluded

For Part A study subjects only

  • Use of prescription drugs or non-prescription drugs, if in the opinion of the investigator (in consultation with the GSK medical monitor), the medication will interfere with the study procedures or compromise subject safety
  • Subjects must not currently be taking any of the following: topical steroids on the arms, oral or systemic steroids or any other immune-modulators (the washout period will be determined, on a case by case basis, by the investigator in consultation with the GSK medical monitor)
  • Subjects with an aspartate aminotransferase and/or gamma glutamyltransferase level above the upper limit of normal at screening and/or baseline will be excluded.

For Part A (only cohorts with DTH challenge) study subjects only:

  • Use of nicotine patches on the arm at screening that would interfere with the injection sites
  • Presence of tattoos, naevi or other skin abnormalities such as keloids (or a history of keloids) that may, in the opinion of the investigator, interfere with DTH assessments
  • Subjects participating, within seven days of screening, in recreational sun-bathing, or the use of a sun-bed, on the area of the skin from the wrist to the shoulder (inclusive)

For Part B study subjects only:

  • History of significant cardiac, endocrinologic, haematologic, pulmonary, metabolic, renal, hepatic, immunologic (excluding psoriasis and psoriatic arthritis), urologic, neurologic, dermatologic (except psoriasis), psychiatric or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at unacceptable risk
  • Clinically significant abnormalities of laboratory assessments (not related to disease) as judged by the investigator and/or GSK medical monitor
  • All systemic psoriasis medications, including psoralen long-wave ultraviolet radiation treatments, or other systemic immunosuppressives, are not allowed within 5 half lives prior to Day-1 (Methotrexate and cyclosporin are not allowed within 8 weeks of Day -1; Psoralen long-wave Ultraviolet (UV) is not allowed within 4 weeks of Day-1). Subjects should not be included if the investigator considers that the subject is at high risk of requiring rescue with prohibited medication for duration of study up to follow-up. This assessment should be based on current disease activity or a history of frequent and/or severe flares requiring systemic immunosuppression.
  • The use of single treatment phototherapy (ultraviolet B or self treatment with tanning beds) is not allowed within 14 days prior to Day -1
  • The use of topical therapies for psoriasis are not allowed with 7 days prior to Day-1 on the index lesion or biopsy plaque
  • Previous treatment with anti- Tumour necrosis factor (TNF)/ Interleukin (IL)-12/IL-23 or any other monoclonal antibodies is not allowed within 12 weeks prior to Day-1
  • Patients that require narrow therapeutic index medications from Screening to Follow-up
  • Vulnerable subjects (e.g. person kept in detention)
  • Subjects who are not able to understand and communicate in the native language of the country where the study is conducted.
  • Subjects who work for the Sponsor or CRO.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02195349


Locations
Germany
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53127
GSK Investigational Site
Berlin, Germany, 14050
United Kingdom
GSK Investigational Site
Cambridge, United Kingdom, CB2 2GG
GSK Investigational Site
London, United Kingdom
Sponsors and Collaborators
GlaxoSmithKline
Parexel
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02195349     History of Changes
Other Study ID Numbers: 200630
First Posted: July 21, 2014    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018

Keywords provided by GlaxoSmithKline:
Tuberculin Purified Protein Derivative
Delayed Type Hypersensitivity
Biopsy
Induration
First time in human
T-cells
LAG-3
safety
GSK2831781
psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases